NIH Awards Longeveron Cutting-Edge Research Grant to Fight ‘Metabolic Syndrome’ of Obesity, High Blood Pressure, Unhealthy Cholesterol and More through Regenerative Medicine
January 09, 2018
New advances in regenerative medicine could improve the odds for a healthier life for people with metabolic syndrome. The National Institutes of Health’s National Institute on Aging (NIA) recognized this, and recently awarded a prestigious research grant to Longeveron, a regenerative medicine therapy company based in Miami, Florida
NEWS PROVIDED BY
Jan. 09, 2018 09:42 ET
MIAMI, Jan. 9, 2018 /PRNewswire/ — New advances in regenerative medicine could improve the odds for a healthier life for people with metabolic syndrome. The National Institutes of Health’s National Institute on Aging (NIA) recognized this, and recently awarded a prestigious research grant to Longeveron, a regenerative medicine therapy company based in Miami, Florida.
An estimated 1 in 3 American adults live with Metabolic Syndrome every day. Obesity, high blood pressure, and/or increased blood glucose contribute to the risk, and the syndrome can lead to coronary heart disease, stroke, diabetes and — in some cases — even death.
Physicians often recommend diet, exercise and other lifestyle changes as part of a treatment plan. The goal is to help people lose weight, stay physically active and get more engaged in their health and wellness. But committing to significant behavioral change remains challenging for many people with Metabolic Syndrome, often long after New Year’s resolutions dissolve.
The company’s investigators plan to use the research award to conduct Phase 1 and 2 clinical trials of Longeveron mesenchymal stem cells (LMSCs) to improve the outlook for people with Metabolic Syndrome. LMSC therapy represents a much-needed novel approach — targeting the drivers of Metabolic Syndrome at a cellular level. The company will study Metabolic Syndrome in connection with Aging Frailty, a clinically defined wasting syndrome that increases vulnerability to morbidity, injury and death. There is a high incidence of Metabolic Syndrome among Aging Frailty subjects, and both are characterized by a pro-inflammatory state which LMSCs are intended to reduce.
“The award makes possible development of life-altering therapies that could be delivered alone or in combination with existing medications to reverse the development or progression of Metabolic Syndrome,” said Anthony Oliva, Ph.D., who will serve as an investigator. “LMSC-based therapies could, in the future, alleviate many of the risk factors that put many people with Metabolic Syndrome on a path toward life-threatening conditions.”
This Small Business Technology Transfer grant will fund over $1.15 million as part of the NIH Fast Track program for small businesses. The current grant represents the third funding award for Longeveron, which has previously received financial support from the Alzheimer’s Association and Maryland’s TEDCO for clinical trials in Alzheimer’s disease and Hypoplastic Left Heart Syndrome, respectively.
To learn more about the clinical trial, including criteria for participating,
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron’s MSCs are also approved for use in the Bahamas. As the only company to have a locally-approved allogeneic stem cell treatment, Longeveron currently is conducting a single-arm open label clinical trial for Aging Frailty in the Bahamas and is planning to add other indications to its Bahamas trial including cognitive disorders and orthopedic conditions.
Longeveron () is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
SOURCE Longeveron LLC